38920 Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices 

awards (currently active grants, 

cooperative agreements, and 

procurement contracts) greater than 

$10,000,000 for any period of time 

during the period of performance of an 

award/project. 

Mandatory Disclosure Requirements 

As required by 2 CFR part 200 of the 

Uniform Guidance, and the HHS 

implementing regulations at 45 CFR part 

75, effective January 1, 2016, the IHS 

must require a non-federal entity or an 

applicant for a federal award to disclose, 

in a timely manner, in writing to the 

IHS or pass-through entity all violations 

of federal criminal law involving fraud, 

bribery, or gratuity violations 

potentially affecting the federal award. 

Submission is required for all 

applicants and recipients, in writing, to 

the IHS and to the HHS Office of 

Inspector General all information 

related to violations of federal criminal 

law involving fraud, bribery, or gratuity 

violations potentially affecting the 

federal award. 45 CFR 75.113. 

Disclosures must be sent in writing to: 

U.S. Department of Health and Human 

Services, Indian Health Service, 

Division of Grants Management, ATTN: 

Robert Tarwater, Director, 5600 Fishers 

Lane, Mail Stop: 09E70. 

Rockville, MD 20857 

(Include ‘‘Mandatory Grant 

Disclosures’’ in subject line) 

Office: (301) 443–5204. 

Fax: (301) 594–0899. 

Email: Robert.Tarwater@ihs.gov. 

AND 

U.S. Department of Health and 

Human Services, Office of Inspector 

General, ATTN: Mandatory Grant 

Disclosures, Intake Coordinator, 330 

Independence Avenue SW., Cohen 

Building, Room 5527, Washington, DC 

20201, URL: http://oig.hhs.gov/fraud/ 

report-fraud/index.asp. 

(Include ‘‘Mandatory Grant 

Disclosures’’ in subject line) 

Fax: (202) 205–0604 (Include 

‘‘Mandatory Grant Disclosures’’ in 

subject line) or 

Email: 

MandatoryGranteeDisclosures@

oig.hhs.gov 

Failure to make required disclosures 

can result in any of the remedies 

described in 45 CFR 75.371 Remedies 

for noncompliance, including 

suspension or debarment (See 2 CFR 

parts 180 & 376 and 31 U.S.C. 3321). 

VII. Agency Contacts 

1. Questions on the programmatic 

issues may be directed to: Lisa C. Neel, 

MPH, Public Health Advisor, Office of 

Public Health Support, Division of 

Epidemiology & Disease Prevention, 

Indian Health Service, 5600 Fishers 

Lane, Mailstop: 09E17B, Rockville, MD 

20857, Phone: (301) 443–4305, E-Mail: 

Lisa.Neel@ihs.gov. 

2. Questions on grants management 

and fiscal matters may be directed to: 

John Hoffman, Senior Grants 

Management Specialist, IHS Division of 

Grants Management, 5600 Fishers Lane, 

Mailstop: 09E70, Rockville, MD 20857, 

Phone: (301) 443–2116, E-Mail: 

John.Hoffman@ihs.gov. 

3. Questions on systems matters may 

be directed to: Paul Gettys, Grant 

Systems Coordinator, 5600 Fishers 

Lane, Mail Stop: 09E70, Rockville, MD 

20857, Phone: (301) 443–2114; or the 

DGM main line (301) 443–5204, Fax: 

(301) 594–0899, E-Mail: Paul.Gettys@

ihs.gov. 

VIII. Other Information 

The Public Health Service strongly 

encourages all cooperative agreement 

and contract recipients to provide a 

smoke-free workplace and promote the 

non-use of all tobacco products. In 

addition, Public Law 103–227, the ProChildren Act of 1994, prohibits smoking 

in certain facilities (or in some cases, 

any portion of the facility) in which 

regular or routine education, library, 

day care, health care, or early childhood 

development services are provided to 

children. This is consistent with the 

HHS mission to protect and advance the 

physical and mental health of the 

American people. 

Dated: August 10, 2017. 

Michael D. Weahkee, 

RADM, Assistant Surgeon General, U.S. 

Public Health Service, Acting Director, Indian 

Health Service. 

[FR Doc. 2017–17311 Filed 8–15–17; 8:45 am] 

BILLING CODE 4160–16–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–17–270: 

NIDDK Biorepositories Sample Access. 

Date: September 21, 2017. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Multi-Center 

Clinical Applications (PA–16–160). 

Date: September 25, 2017. 

Time: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–17–123: 

NIDDK Biomarker R01s on Biorepository 

Samples. 

Date: September 27, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–15–068: 

NIDDK Multi-Center Clinical Study 

Implementation Planning Cooperative 

Agreements (U34). 

Date: September 28, 2017. 

Time: 3:30 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices 38921 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: August 10, 2017. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–17280 Filed 8–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Clinical and Translational R21 and Omnibus 

R03: SEP 3. 

Date: September 25–26, 2017. 

Time: 8:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Arlington Gateway, 801 

N. Glebe Road, Arlington, VA 22203. 

Contact Person: Robert Stephen Coyne, 

Ph.D., Scientific Review Officer, Research 

Program Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W236, Bethesda, MD 20892–9750, 

240–276–5120, coynes@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, R25 

Education. 

Date: September 27, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W608, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Robert E. Bird, Ph.D., 

Scientific Review Officer, Research Program, 

Review Branch Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W608, 

Bethesda, MD, 20892–9750, 240–276–6344, 

birdr@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project I. 

Date: October 12–13, 2017. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Anita T. Tandle, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W248, 

Bethesda, MD 20892–9750, 240–276–5007, 

tandlea@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR Phase 

II Bridge Awards. 

Date: October 12, 2017. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Jeffrey E. DeClue Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W238, Bethesda, MD 20892– 

9750, 240–276–6371, decluej@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project II (P01). 

Date: October 17–18, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike Rockville, MD 20852. 

Contact Person: Sanita Bharti, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W122, 

Bethesda, MD 20892–9750, 240–276–5909, 

sanitab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Program Project III (P01). 

Date: October 17–18, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Mukesh Kumar, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W618, 

Bethesda, MD 20892–9750, 240–276–6611, 

sanitab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Provocative 

Questions: SEP 4. 

Date: October 20, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Bethesda, MD 

20892–9750, 240–276–5122, hasan.siddiqui@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, NCI 

Clinical and Translational R21 and Omnibus 

R03: SEP–1. 

Date: October 25–26, 2017. 

Time: 8:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Byeong-Chel Lee, Ph.D., 

Scientific Review Officer Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W238, Bethesda, MD 20892–9750 

240–276–7755 byeong-chel.lee@nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group, NCI Clinical 

and Translational R21 and Omnibus R03: 

SEP–4. 

Date: October 25–26, 2017. 

Time: 6:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20892–9750. 

Contact Person: Eduardo E. Chufan, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Bethesda, MD 20892– 

9750, 240–276–7975, chufanee@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, R01 

Review Teleconference. 

Date: October 31, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W608, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Robert E. Bird, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W608, 

Bethesda, MD 20892–9750, 240–276–6344, 

birdr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 


asabaliauskas on DSKBBXCHB2PROD with NOTICES